Clinical Research Directory

Inclusion Criteria: * \- Obtaining informed consent to participate in the study. * Morphologically confirmed gastric adenocarcinoma. * The presence of localized or locally advanced gastric cancer (cT2-4a and/or N+) * The full volume of the planned neoadjuvant component of perioperative chemotherapy was performed * Radical surgical intervention was performed for the primary tumor of gastric cancer * The histological degree of tumor regression after surgical resection was classified TRG1 and without metastasis to regional lymph nodes N0 or TRG 4-5 based on the Mandard tumor Regression scale. * ECOG score 0 - I. * Absence of severe uncontrolled concomitant chronic and acute diseases. * Adequate liver and bone marrow function * Neutrophils \> 1.5\*109/l * Hemoglobin \>85 g/l * Platelets \>100\*109/l * Increased transaminases and/or bilirubin \< 2 art. Exclusion Criteria: * Lack of a neoadjuvant component of perioperative chemotherapy or insufficient number of courses * The time after surgical treatment is more than 12 weeks * Stage IV of the disease * Her2-positive and/or MSI\\dMMR stomach cancer * Severe uncontrolled concomitant chronic or acute diseases * The presence of a second malignant tumor (with the exception of previously cured malignant neoplasms) * Any conditions that, in the opinion of the doctor, interfere with the examination procedures * With incomplete tumor response to treatment